Rituximab news

• 

  20 April 2026

  FDA Accepts Genentech sBLA for Gazyva in SLE

  FDA accepted sBLA for an anti‑CD20 in SLE after Phase III ALLEGORY: SRI‑4 responders 76.7% vs 53.5%, higher remission, fewer flares and steroid reduction; decision due Dec 2026.
• 

  9 April 2026

  Zenyaku Kogyo and Chugai end Rituxan co-promotion in Japan effective Sept 3, 2026

  Rituxan co-promotion in Japan ends Sept 3, 2026. One partner will cease sales on sell-out; the other assumes sole sales and medical information from Sept 4. Transition to ensure stable supply.
• 

  23 March 2026

  Chugai obtains MHLW approval for Lunsumio–Polivy combo in relapsed/refractory large B‑cell lymphoma

  Japan approves Lunsumio + Polivy for relapsed/refractory large B‑cell lymphoma after Phase III SUNMO: ORR 69.7%, PFS 11.5 vs 3.8 months (59% lower progression/death risk); manageable safety.
• 

  19 February 2026

  Zenyaku's Rituxan Approved for Autoimmune Hemolytic Anemia Treatment

  Rituxan gains approval for treating autoimmune hemolytic anemia, targeting B cells to reduce autoantibodies. Effective for warm AIHA, CAD, and PCH, offering an alternative to steroids.
• 

  17 February 2026

  Genmab Releases 2025 Annual Report

  The report highlights 2025 achievements, financials, and 2026 outlook, including revenue growth, strategic acquisitions, and regulatory approvals.
• 

  16 January 2026

  Genmab Reports Phase 3 Trial Results for Epcoritamab in Relapsed/Refractory DLBCL

  Epcoritamab shows improved progression-free survival in Phase 3 trial for R/R DLBCL. Safety profile consistent. Further analysis and regulatory discussions planned.

• 

  9 December 2025

  Lilly's Jaypirca Improves Progression-Free Survival in Treatment-Naïve CLL/SLL

  Jaypirca reduced disease progression risk by 80% in CLL/SLL patients, showing promising safety and efficacy in a Phase 3 trial, with fewer adverse events compared to chemoimmunotherapy.
• 

  7 December 2025

  Genmab's Phase 3 Trial Shows EPKINLY + R2 Benefits in Relapsed Follicular Lymphoma

  EPKINLY + R2 reduces disease progression risk by 79% in relapsed follicular lymphoma, with a 95% response rate. FDA-approved, it offers a new second-line treatment option.
• 

  18 November 2025

  Genmab's EPKINLY Combination Approved by FDA for Relapsed Follicular Lymphoma

  EPKINLY + R² shows superior progression-free survival and response rates in Phase 3 trial for relapsed follicular lymphoma, with a consistent safety profile.